Tag Archives: cardiac immune-related adverse events

Introduction Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, significantly improving survival across many tumour types. For instance, the 10-year results of the CheckMate-067 trial in metastatic melanoma reported a 43% overall survival (OS) rate, compared with under 5% before ICIs.1 ICIs function by inhibiting regulatory proteins expressed by immune cells, reducing self-tolerance and enhancing the immune system’s ability to recognise tumour cells. Most commercially available ICIs target the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1)